Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

BMC Cancer

Table 3 Response to treatment in relation to biomarkers expression considered as per clinical practice^a

	No.	CR or PR or SD	PD	p
	No.	No. (%)	No. (%)	p
ER status
< 1%	1	0	1 (100)
≥ 1%	72	64 (88.9)	8 (11.1)	0.123
PgR status
< 1%	15	11 (73.3)	4 (26.7)
≥ 1%	58	53 (91.4)	5 (8.6)	0.079
Ki67 status
< 20%	46	44 (95.7)	2 (4.3)
≥ 20%	26	19 (73.1)	7 (26.9)	0.009
HER2 status
Negative	64	57 (89.1)	7 (10.9)
Positive	9	7 (77.8)	2 (22.2)	0.306
AR status
< 1%	12	10 (83.3)	2 (16.7)
≥ 1%	61	54 (88.5)	7 (11.5)	0.619
< 10%	19	15 (79.0)	4 (21.0)
≥ 10%	54	49 (90.7)	5 (9.3)	0.182
AR/ER ratio
< 0.90 (best cutoff)	38	31 (81.6)	7 (18.4)
≥ 0.90 (best cutoff)	35	33 (94.3)	2 (5.7)	0.101
AR/PgR ratio
< 0.96 (best cutoff)	27	23 (85.2)	4 (14.8)
≥ 0.96 (best cutoff)	46	41 (89.1)	5 (10.9)	0.623

Abbreviations: CR complete response, PR partial response, SD stable disease, PD progressive disease, ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
^abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed

ISSN: 1471-2407